NO314486B1 - Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform - Google Patents
Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform Download PDFInfo
- Publication number
- NO314486B1 NO314486B1 NO19971539A NO971539A NO314486B1 NO 314486 B1 NO314486 B1 NO 314486B1 NO 19971539 A NO19971539 A NO 19971539A NO 971539 A NO971539 A NO 971539A NO 314486 B1 NO314486 B1 NO 314486B1
- Authority
- NO
- Norway
- Prior art keywords
- phenylalanine
- lofepramine
- preparation
- tyrosine
- antidepressant
- Prior art date
Links
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 title claims abstract description 43
- 201000006417 multiple sclerosis Diseases 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 10
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 title claims abstract description 9
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 title claims abstract description 9
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 title claims abstract description 9
- 238000011282 treatment Methods 0.000 title claims description 18
- 239000000935 antidepressant agent Substances 0.000 title claims description 17
- 229940005513 antidepressants Drugs 0.000 title claims description 14
- 230000001430 anti-depressive effect Effects 0.000 title claims description 12
- 239000002552 dosage form Substances 0.000 title claims description 8
- 238000002360 preparation method Methods 0.000 title claims description 7
- 230000003210 demyelinating effect Effects 0.000 title claims description 5
- 229960002813 lofepramine Drugs 0.000 claims description 26
- SAPNXPWPAUFAJU-UHFFFAOYSA-N lofepramine Chemical compound C12=CC=CC=C2CCC2=CC=CC=C2N1CCCN(C)CC(=O)C1=CC=C(Cl)C=C1 SAPNXPWPAUFAJU-UHFFFAOYSA-N 0.000 claims description 26
- 229960005190 phenylalanine Drugs 0.000 claims description 24
- 239000011782 vitamin Substances 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 6
- 239000007924 injection Substances 0.000 claims description 6
- 229940024606 amino acid Drugs 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 229960000836 amitriptyline Drugs 0.000 claims description 4
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims description 4
- 229960004801 imipramine Drugs 0.000 claims description 4
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 claims description 4
- 229960004441 tyrosine Drugs 0.000 claims description 4
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 claims description 3
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 claims description 3
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims description 3
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 claims description 3
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 claims description 3
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 3
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 claims description 3
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 claims description 3
- DPWPWRLQFGFJFI-UHFFFAOYSA-N Pargyline Chemical compound C#CCN(C)CC1=CC=CC=C1 DPWPWRLQFGFJFI-UHFFFAOYSA-N 0.000 claims description 3
- 229960004606 clomipramine Drugs 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 3
- 229960003914 desipramine Drugs 0.000 claims description 3
- 229960005426 doxepin Drugs 0.000 claims description 3
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 claims description 3
- 229960004090 maprotiline Drugs 0.000 claims description 3
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 claims description 3
- 229960003955 mianserin Drugs 0.000 claims description 3
- 229960004644 moclobemide Drugs 0.000 claims description 3
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001158 nortriptyline Drugs 0.000 claims description 3
- 229960001779 pargyline Drugs 0.000 claims description 3
- -1 pheneizine Chemical compound 0.000 claims description 3
- 229960002601 protriptyline Drugs 0.000 claims description 3
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 claims description 3
- 229960003741 tranylcypromine Drugs 0.000 claims description 3
- OVCXRBARSPBVMC-UHFFFAOYSA-N triazolopyridine Chemical compound C=1N2C(C(C)C)=NN=C2C=CC=1C=1OC=NC=1C1=CC=C(F)C=C1 OVCXRBARSPBVMC-UHFFFAOYSA-N 0.000 claims description 3
- 229960002431 trimipramine Drugs 0.000 claims description 3
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 claims description 3
- 229960004688 venlafaxine Drugs 0.000 claims description 3
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001255 viloxazine Drugs 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 229940123445 Tricyclic antidepressant Drugs 0.000 abstract description 3
- 239000003029 tricyclic antidepressant agent Substances 0.000 abstract description 3
- 201000002491 encephalomyelitis Diseases 0.000 abstract 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 7
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000002858 neurotransmitter agent Substances 0.000 description 6
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 230000036407 pain Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 206010021639 Incontinence Diseases 0.000 description 3
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
- 208000008238 Muscle Spasticity Diseases 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 3
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 3
- 229940076279 serotonin Drugs 0.000 description 3
- 208000018198 spasticity Diseases 0.000 description 3
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- INQLNSVYIFCUML-QZTLEVGFSA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2r,3s,4r,5r)-5-(4-carbamoyl-1,3-thiazol-2-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=N1 INQLNSVYIFCUML-QZTLEVGFSA-N 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- 229960000964 phenelzine Drugs 0.000 description 2
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004799 tryptophan Drugs 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 229960001393 dosulepin Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000001667 episodic effect Effects 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007108 local immune response Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 229940053544 other antidepressants in atc Drugs 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 208000026473 slurred speech Diseases 0.000 description 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- PHTUQLWOUWZIMZ-GZTJUZNOSA-N trans-dothiepin Chemical compound C1SC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 PHTUQLWOUWZIMZ-GZTJUZNOSA-N 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000018405 transmission of nerve impulse Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Molecular Biology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Control Of Indicators Other Than Cathode Ray Tubes (AREA)
- Control Of El Displays (AREA)
- Fodder In General (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9420116A GB9420116D0 (en) | 1994-10-05 | 1994-10-05 | A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions |
GBGB9508482.8A GB9508482D0 (en) | 1995-04-26 | 1995-04-26 | A therapeutic drug treatment for compensating for the effects of nerve damage caused by multiple sclerosis and other demyelinating conditions, and the product |
PCT/GB1995/002361 WO1996011009A1 (en) | 1994-10-05 | 1995-10-05 | Treatment of multiple sclerosis (ms) and other demyelinating conditions using lofepramine in combination with l-phenylalanine, tyrosine or tryptophan and possibly a vitamin b12 compound |
Publications (3)
Publication Number | Publication Date |
---|---|
NO971539L NO971539L (no) | 1997-04-04 |
NO971539D0 NO971539D0 (no) | 1997-04-04 |
NO314486B1 true NO314486B1 (no) | 2003-03-31 |
Family
ID=26305745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19971539A NO314486B1 (no) | 1994-10-05 | 1997-04-04 | Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform |
Country Status (19)
Country | Link |
---|---|
US (2) | US6096737A (fi) |
EP (1) | EP0784476B1 (fi) |
JP (1) | JPH10508583A (fi) |
AT (1) | ATE227124T1 (fi) |
AU (1) | AU710339B2 (fi) |
CA (1) | CA2200761C (fi) |
CZ (1) | CZ293873B6 (fi) |
DE (1) | DE69528773T2 (fi) |
DK (1) | DK0784476T3 (fi) |
ES (1) | ES2184808T3 (fi) |
FI (1) | FI116659B (fi) |
HU (1) | HU225493B1 (fi) |
IS (1) | IS1956B (fi) |
NO (1) | NO314486B1 (fi) |
NZ (1) | NZ293642A (fi) |
PL (1) | PL181802B1 (fi) |
PT (1) | PT784476E (fi) |
SK (1) | SK281932B6 (fi) |
WO (1) | WO1996011009A1 (fi) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998001157A1 (en) * | 1996-07-05 | 1998-01-15 | The Wwk Trust | Compositions for the treatment of peripheral neuropathies containing antidepressants and/or monoamine oxidase inhibitors and/or vitamin b12 and/or precursors or inducers of a neurotransmitter |
GB9617990D0 (en) | 1996-08-29 | 1996-10-09 | Scotia Holdings Plc | Treatment of pain |
EP0835660A1 (en) * | 1996-10-14 | 1998-04-15 | Gaston Edmond Filomena Merckx | Products containing methylcobalamin for the treatment of multiple sclerosis or other demyelinating conditions |
US7232830B2 (en) * | 1998-06-26 | 2007-06-19 | Elaine A Delack | Method for treatment of neurodegenerative diseases and effects of aging |
GB9904252D0 (en) * | 1999-02-24 | 1999-04-21 | Worsley Andrew P | Composition for the treatment of pain |
GB9906808D0 (en) * | 1999-03-24 | 1999-05-19 | Kilgowan Limited | Formulation for treatment of pain |
GB2355191A (en) * | 1999-10-12 | 2001-04-18 | Laxdale Ltd | Combination formulations for fatigue, head injury and strokes |
CA2417960C (en) | 2000-08-04 | 2012-07-10 | Dmi Biosciences, Inc. | Method of using diketopiperazines and composition containing them |
US8394813B2 (en) | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US20020147206A1 (en) * | 2001-04-05 | 2002-10-10 | Pfizer Inc. | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy |
GB0216027D0 (en) | 2002-07-10 | 2002-08-21 | Arachnova Therapeutics Ltd | New therapeutic use |
US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US6833142B2 (en) * | 2002-03-14 | 2004-12-21 | Duane Bennett | Formulation for the prevention and treatment of multiple sclerosis and other demyelinating conditions |
DK1571970T3 (da) | 2002-10-02 | 2011-11-28 | Dmi Biosciences Inc | Diagnose og monitorering af sygdomme |
EP1599212A4 (en) * | 2003-02-14 | 2006-02-08 | Combinatorx Inc | POLYTHERAPY FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS |
CN104095851A (zh) * | 2003-05-15 | 2014-10-15 | 安皮奥制药股份有限公司 | T-细胞介导的疾病的治疗 |
GB0313630D0 (en) * | 2003-06-12 | 2003-07-16 | Wwk Trust The | Compositions for the enhanced treatment of depression |
US20050192261A1 (en) * | 2003-09-15 | 2005-09-01 | Jost-Price Edward R. | Methods and reagents for the treatment of immunoinflammatory disorders |
WO2007100668A2 (en) | 2006-02-24 | 2007-09-07 | Shire Llc | Antidepressant prodrugs |
EP2300011A4 (en) | 2008-05-27 | 2012-06-20 | Dmi Life Sciences Inc | METHODS AND THERAPEUTIC COMPOUNDS |
WO2011011594A2 (en) * | 2009-07-23 | 2011-01-27 | Shriners Hospitals For Children | Intracellular toll-like receptors pathways and axonal degeneration |
US8507496B2 (en) | 2010-09-07 | 2013-08-13 | Dmi Acquisition Corp. | Treatment of diseases |
PL2766029T3 (pl) | 2011-10-10 | 2020-08-24 | Ampio Pharmaceuticals, Inc. | Leczenie choroby zwyrodnieniowej stawów |
KR20140075772A (ko) | 2011-10-10 | 2014-06-19 | 앰피오 파마슈티컬스 인코퍼레이티드 | 면역 내성을 증가시킨 이식 의료 장비, 및 그의 제조 및 이식 방법 |
CN103841974A (zh) | 2011-10-28 | 2014-06-04 | 安皮奥制药股份有限公司 | 鼻炎的治疗 |
MX2015010937A (es) | 2013-03-15 | 2015-10-29 | Ampio Pharmaceuticals Inc | Composiciones para la movilizacion, autodireccion, expansion y diferenciacion de celulas madre y metodos para usar las mismas. |
CA2958080A1 (en) | 2014-08-18 | 2016-02-25 | Ampio Pharmaceuticals, Inc. | Treatment of joint conditions |
EP3310375A4 (en) | 2015-06-22 | 2019-02-20 | Ampio Pharmaceuticals, Inc. | USE OF LOW MOLECULAR WEIGHT HUMAN SERUM ALBUMIN FRACTIONS FOR TREATING DISEASES |
GB2544630A (en) | 2015-11-19 | 2017-05-24 | The Wwk Trust | Combinations for the treatment of dementia, and the enhancement of cognitive function |
CA3041358A1 (en) * | 2016-10-25 | 2018-05-03 | Uti Limited Partnership | Treatment for progressive multiple sclerosis |
CA3061340A1 (en) | 2017-04-25 | 2018-11-01 | Temple Otorongo Llc | Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions |
EP3431491A1 (en) * | 2017-07-18 | 2019-01-23 | Centre National De La Recherche Scientifique | Methods for purifying proteins having a tubulin carboxypeptidase activity and peptidic based inhibitors thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1497306A (en) * | 1975-07-03 | 1978-01-05 | Leo Ab | Preparation of lofepramine and its hydrochloride |
GB2082910A (en) * | 1980-08-28 | 1982-03-17 | Berk Pharmaceuticals Ltd | Anti-depressant compositions |
US4409243A (en) * | 1981-11-09 | 1983-10-11 | Julian Lieb | Treatment of auto-immune and inflammatory diseases |
GB2129299A (en) * | 1982-11-09 | 1984-05-16 | Alec James Coppen | Pharmaceutical compositions |
DE3519687A1 (de) * | 1985-06-01 | 1986-12-04 | Veit Arend | Aminosaeuren enthaltendes arzneimittel |
US4650789A (en) * | 1985-10-15 | 1987-03-17 | Commonwealth Medical Corporation Of America | Method and composition for increasing production of serotonin |
US4843071A (en) * | 1986-12-05 | 1989-06-27 | Serotonin Industries Of Charleston | Method and composition for treating obesity, drug abuse, and narcolepsy |
DE4204102C2 (de) * | 1992-02-12 | 1998-09-24 | Kragler Peter | Arzneimittel zur Behandlung und/oder Prophylaxe von AIDS und anderen verwandten Erkrankungen |
-
1995
- 1995-10-05 WO PCT/GB1995/002361 patent/WO1996011009A1/en active IP Right Grant
- 1995-10-05 HU HU9702373A patent/HU225493B1/hu not_active IP Right Cessation
- 1995-10-05 AT AT95933488T patent/ATE227124T1/de not_active IP Right Cessation
- 1995-10-05 DE DE69528773T patent/DE69528773T2/de not_active Expired - Lifetime
- 1995-10-05 AU AU36126/95A patent/AU710339B2/en not_active Ceased
- 1995-10-05 SK SK438-97A patent/SK281932B6/sk not_active IP Right Cessation
- 1995-10-05 ES ES95933488T patent/ES2184808T3/es not_active Expired - Lifetime
- 1995-10-05 PL PL95319830A patent/PL181802B1/pl not_active IP Right Cessation
- 1995-10-05 US US08/817,086 patent/US6096737A/en not_active Expired - Lifetime
- 1995-10-05 CZ CZ1997995A patent/CZ293873B6/cs not_active IP Right Cessation
- 1995-10-05 DK DK95933488T patent/DK0784476T3/da active
- 1995-10-05 NZ NZ293642A patent/NZ293642A/xx not_active IP Right Cessation
- 1995-10-05 JP JP8512415A patent/JPH10508583A/ja active Pending
- 1995-10-05 EP EP95933488A patent/EP0784476B1/en not_active Expired - Lifetime
- 1995-10-05 CA CA002200761A patent/CA2200761C/en not_active Expired - Fee Related
- 1995-10-05 PT PT95933488T patent/PT784476E/pt unknown
-
1997
- 1997-03-26 IS IS4454A patent/IS1956B/is unknown
- 1997-03-26 FI FI971290A patent/FI116659B/fi active IP Right Grant
- 1997-04-04 NO NO19971539A patent/NO314486B1/no not_active IP Right Cessation
-
2000
- 2000-06-01 US US09/584,401 patent/US6569850B1/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE69528773T2 (de) | 2003-09-04 |
EP0784476B1 (en) | 2002-11-06 |
FI971290A (fi) | 1997-06-02 |
JPH10508583A (ja) | 1998-08-25 |
PL319830A1 (en) | 1997-09-01 |
IS1956B (is) | 2004-11-15 |
DE69528773D1 (de) | 2002-12-12 |
DK0784476T3 (da) | 2003-03-17 |
NZ293642A (en) | 1998-10-28 |
CZ99597A3 (en) | 1997-11-12 |
FI116659B (fi) | 2006-01-31 |
WO1996011009A1 (en) | 1996-04-18 |
IS4454A (is) | 1997-03-26 |
SK281932B6 (sk) | 2001-09-11 |
HU225493B1 (en) | 2007-01-29 |
CA2200761C (en) | 2008-02-26 |
CA2200761A1 (en) | 1996-04-18 |
PL181802B1 (en) | 2001-09-28 |
ES2184808T3 (es) | 2003-04-16 |
CZ293873B6 (cs) | 2004-08-18 |
AU3612695A (en) | 1996-05-02 |
US6096737A (en) | 2000-08-01 |
AU710339B2 (en) | 1999-09-16 |
SK43897A3 (en) | 1998-08-05 |
PT784476E (pt) | 2003-03-31 |
NO971539L (no) | 1997-04-04 |
HUT77380A (hu) | 1998-04-28 |
FI971290A0 (fi) | 1997-03-26 |
ATE227124T1 (de) | 2002-11-15 |
EP0784476A1 (en) | 1997-07-23 |
NO971539D0 (no) | 1997-04-04 |
US6569850B1 (en) | 2003-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO314486B1 (no) | Anvendelse av et antidepressivt middel i kombinasjon med fenylalanin ellertyrosin for tillaging av medisin for behandling av multippelsklerose eller andre demyelinerende tilstander, samt et kombinasjonspreparat og enenhetsdoseform | |
Kita et al. | Drugs used to treat spasticity | |
Detke et al. | Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression | |
Igel et al. | Practical use of pharmacotherapy for obesity | |
Pare | The present status of monoamine oxidase inhibitors | |
Kasper et al. | Panic disorder: the place of benzodiazepines and selective serotonin reuptake inhibitors | |
Greene et al. | Baclofen in the treatment of idiopathic dystonia in children | |
Larrison-Faucher et al. | Nicotine reduces antisaccade errors in task impaired schizophrenic subjects | |
Fabbri et al. | Adjunctive therapies in Parkinson’s disease: how to choose the best treatment strategy approach | |
O’Brien et al. | Spasticity after stroke: epidemiology and optimal treatment | |
Clanet et al. | The management of multiple sclerosis patients | |
Cross et al. | A perspective on cannabinoids for treating epilepsy: do they really change the landscape? | |
La Spina et al. | Gabapentin in painful HIV‐related neuropathy: a report of 19 patients, preliminary observations | |
US11369619B2 (en) | Composition for curing migraine headaches | |
Fine | Ethical and practical issues with opioids in life-limiting illness | |
SOLYOM et al. | Trazodone treatment of bulimia nervosa | |
Haas et al. | Neurological effects of glutethimide. | |
Sahoo et al. | Rehabilitation of organophosphate induced delayed polyneuropathy | |
Quazi | The Study of Drug Utilisation Evaluation of Benzodiazepine Derivatives and Antipsychotic Drugs Prescribed in Tertiary Care Hospital | |
Heebink et al. | Psychopharmacology in adolescents with eating disorders | |
Furmanski | BAL therapy in infectious and metabolic neuropathies | |
Rumrill Jr et al. | Multiple sclerosis: Etiology, incidence and prevalence | |
Meara | The Drug Treatment of | |
Bradford et al. | Therapy: Recent Progress in Clinical Applications and Research in Fibromyalgia--Part 3 | |
Engel et al. | Aging of the human neuromuscular system: patient vignettes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |